Dr. Reddy's Laboratories Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dr. Reddy's Laboratories Ltd.
The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies.
Mead Johnson pulls challenged claims before National Advertising Division began a review in its SWIFT process, but not before Nestlé Nutrition, which markets Gerber infant formula, submitted its challenge.
Advisory board for CRN-operated Supplement OWL recently reached out to industry for “ultimate reason” of recruiting participation. “Transparency has never been more important and this registry is a demonstration of this industry’s commitment to candor and honesty with our regulators, retailers and consumers,” they say.
Plus deals involving Y-Biologics/Pierre Fabre, Contera/Abzu, Chugai/Alebund, Catalyst/DyDo, Spergogenix/Abbiska, Nippon Gene/ERS Genomics, Simcere/Vivoryon, Dr. Reddy’s/Journey Medical and Innovent/Synaffix.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Aurigene Discovery Technologies
- OctoPlus N.V.
- Promius Pharma LLC
- Dr. Reddy's Research and Development B.V.
- Imperial Credit Private Limited
- Wockhardt Limited